Patents by Inventor Gary Park

Gary Park has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Prodrugs of Nrf2 activating compounds and uses thereof
    Patent number: 10889562
    Abstract: Aspects of the present disclosure include prodrugs of compounds that activate Nrf2. Such prodrugs find use in the treatment of autoimmune and inflammatory diseases and disorders, such as for example psoriasis and multiple sclerosis. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these prodrugs, methods of using these prodrugs in the treatment of various diseases and disorders, processes for preparing these prodrugs and intermediates useful in these processes.
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: January 12, 2021
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Jiaxin Yu, Beth Fernandez, Gary Park, Ihab Darwish
  • Prodrugs of Nrf2 Activating Compounds and Uses Thereof
    Publication number: 20200369644
    Abstract: Aspects of the present disclosure include prodrugs of compounds that activate Nrf2. Such prodrugs find use in the treatment of autoimmune and inflammatory diseases and disorders, such as for example psoriasis and multiple sclerosis. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these prodrugs, methods of using these prodrugs in the treatment of various diseases and disorders, processes for preparing these prodrugs and intermediates useful in these processes.
    Type: Application
    Filed: August 12, 2020
    Publication date: November 26, 2020
    Inventors: Jiaxin Yu, Beth Fernandez, Gary Park, Ihab Darwish
  • Prodrugs of NRF2 activating compounds and uses thereof
    Patent number: 10774066
    Abstract: Aspects of the present disclosure include prodrugs of compounds that activate Nrf2. Such prodrugs find use in the treatment of autoimmune and inflammatory diseases and disorders, such as for example psoriasis and multiple sclerosis. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these prodrugs, methods of using these prodrugs in the treatment of various diseases and disorders, processes for preparing these prodrugs and intermediates useful in these processes.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: September 15, 2020
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Jiaxin Yu, Beth Fernandez, Gary Park, Ihab Darwish
  • Prodrugs of NRF2 Activating Compounds and Uses Thereof
    Publication number: 20190367472
    Abstract: Aspects of the present disclosure include prodrugs of compounds that activate Nrf2. Such prodrugs find use in the treatment of autoimmune and inflammatory diseases and disorders, such as for example psoriasis and multiple sclerosis. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these prodrugs, methods of using these prodrugs in the treatment of various diseases and disorders, processes for preparing these prodrugs and intermediates useful in these processes.
    Type: Application
    Filed: May 14, 2019
    Publication date: December 5, 2019
    Inventors: Jiaxin Yu, Beth Fernandez, Gary Park, Ihab Darwish
  • Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
    Patent number: 7498353
    Abstract: The present invention relates to prodrugs and compositions thereof useful for treating or preventing Hepatitis C virus (HCV) infections. In particular, the present invention relates to prodrugs of substituted diphenyl-, diheteroaryl- and mixed phenyl heteroaryl substituted five-membered heterocycle compounds, compositions comprising the compounds and the use of such compounds and compositions to inhibit HCV replication and/or proliferation as a therapeutic approach towards the treatment and/or prevention of HCV infections in humans and animals.
    Type: Grant
    Filed: May 2, 2006
    Date of Patent: March 3, 2009
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Dane Goff, Ihab S. Darwish, Rao S. S. Kolluri, Henry Lu, Gary Park
  • Heterocyclic Anti-Viral Compounds Comprising Metabolizable Moieties And Their Uses
    Publication number: 20060247287
    Abstract: The present invention relates to prodrugs and compositions thereof useful for treating or preventing Hepatitis C virus (HCV) infections. In particular, the present invention relates to prodrugs of substituted diphenyl-, diheteroaryl- and mixed phenyl heteroaryl substituted five-membered heterocycle compounds, compositions comprising the compounds and the use of such compounds and compositions to inhibit HCV replication and/or proliferation as a therapeutic approach towards the treatment and/or prevention of HCV infections in humans and animals.
    Type: Application
    Filed: May 2, 2006
    Publication date: November 2, 2006
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Dane Goff, Ihab Darwish, Rao Kolluri, Henry Lu, Gary Park
  • Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
    Publication number: 20050239751
    Abstract: The present invention relates to substituted prodrug and compositions thereof useful for treating or preventing Hepatitis C virus (HCV) infections. In particular, the present invention relates to prodrugs of substituted diphenyl-, diheteroaryl- and mixed phenyl heteroaryl substituted five-membered heterocycle compounds, compositions comprising the compounds and the use of such compounds and compositions to inhibit HCV replication and/or proliferation as a therapeutic approach towards the treatment and/or prevention of HCV infections in humans and animals.
    Type: Application
    Filed: March 25, 2005
    Publication date: October 27, 2005
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Dane Goff, Rao Kolluri, Ihab Darwish, John Partridge, Robin Cooper, Henry Lu, Gary Park